Providers often fail to consider ehrlichia when treating tick-borne infections

October 01, 2018

Chapel Hill, NC - When a patient presents with signs and symptoms suspicious for a tick-borne illness, medical providers in central North Carolina regularly test for Lyme disease and Rocky Mountain Spotted Fever, but often don't think about Ehrlichia, according to researchers at the University of North Carolina at Chapel Hill. The failure to test for Ehrlichia, even as more and more evidence suggests that the infection may be just as common as other endemic tick-borne diseases, appears to impact patient care with antibiotics prescribed less frequently when testing is not ordered. This study's results and recommendation for increased provider education were recently published in the Center for Disease Control and Prevention's journal Emerging Infectious Diseases.

"Providers order Ehrlichia testing much less frequently than Rocky Mountain Spotted Fever or even Lyme disease, despite the low-incidence of Lyme disease in the state," said Ross Boyce, M.D., M.Sc., the study's lead author and a clinical instructor in the Division of Infectious Diseases at the UNC School of Medicine. "This disparity may be attributable to unfamiliarity with local vector epidemiology, as well as the greater attention given to Rocky Mountain Spotted Fever and Lyme disease in the popular media."

Ehrlichia is an illness caused by the Lone Star Tick, which is found throughout the mid-Atlantic United States. Symptoms typically include fever, headache and muscle aches. Boyce and colleagues performed a retrospective chart review on 194 patients who underwent testing for tick-borne illness at UNC hospitals and associated clinics between June and September 2016.

They found that nearly 80 percent of patients were tested for Rocky Mountain Spotted Fever and two-thirds were tested for Lyme disease. Yet providers ordered testing for Ehrlichia in only one-third of patients. Among the initial results, 37 patients tested positive for Rocky Mountain Spotted Fever, one tested positive for Lyme disease and nine tested positive for Ehrlichia.

Using leftover serum, Boyce and colleagues tested the 124 patient samples that were not initially tested for Ehrlichia. Twenty-five of those samples ultimately tested positive for Ehrlichia, putting the total number of positive results nearly equal with the number of Rocky Mountain Spotted Fever cases.

"Our results demonstrate that Ehrlichia accounted for a large proportion of reactive antibodies among a cohort of individuals with suspected tick-borne illness in Central North Carolina," Boyce said. "These finding provide strong, albeit circumstantial evidence that Ehrlichia infection is as prevalent as Rocky Mountain Spotted Fever even as providers appear to consider this diagnosis much less frequently than other tick-borne diseases."

While the CDC guidelines recommend empirical antibiotic treatment when there is suspicion for tick-borne illness, Boyce and colleagues work suggests that providers are less likely to provide antibiotics if testing is not ordered. While it is difficult to distinguish an acute infection from a past exposure with a single test, the study estimates that failure to test for Ehrlichia may have resulted in a missed diagnosis in more than 10 percent of individuals. Boyce said educating front-line providers in primary care clinics and emergency departments about the prevalence of this tick-borne illness is urgently needed.
-end-
The mission of UNC's Institute for Global Health & Infectious Diseases is to harness the full resources of the University and its partners to solve global health problems, reduce the burden of disease, and cultivate the next generation of global health leaders. Learn more at http://www.globalhealth.unc.edu.

University of North Carolina Health Care

Related Lyme Disease Articles from Brightsurf:

Cracking the Lyme disease code
The next time a tick feeds on you, Washington State University researchers hope to make sure persistent arthritis caused by Lyme disease doesn't linger for a lifetime.

Many lyme disease cases go unreported; A new model could help change that
A new model based on 17 years of data can help predict the trajectory of where Lyme disease will spread.

Ethnobotanical medicine is effective against the bacterium causing Lyme disease
A preclinical in vitro study shows that selected plant-based herbal medicines, especially Ghanaian quinine and Japanese knotweed, work better than antibiotics against the bacterium that causes Lyme disease.

Paper-based test could diagnose Lyme disease at early stages
After a day hiking in the forest, the last thing a person wants to discover is a tick burrowing into their skin.

Lyme disease claim lines increased 117% from 2007 to 2018
From 2007 to 2018, claim lines with diagnoses of Lyme disease increased nationally 117%.

New effective vaccines for Lyme disease are coming
There is no effective vaccine currently available to prevent Lyme disease in humans.

New test diagnoses Lyme disease within 15 minutes
Current testing for Lyme disease, called the standard 2-tiered approach or the STT, involves running two complex assays (ELISA and western blot) to detect antibodies against the bacterium, and requires experienced personnel in a lab, and a few hours to carry out and interpret.

An innovative new diagnostic for Lyme disease
In new research, Joshua LaBaer, executive director of the Biodesign Institute at Arizona State University and his colleagues describe an early detection method for pinpointing molecular signatures of the disease with high accuracy.

Mouse, not just tick: New genome heralds change in Lyme disease fight
As Lyme disease increases, researchers have taken a significant step toward finding new ways to prevent its transmission.

Breakthrough paves way for new Lyme disease treatment
Virginia Tech biochemist Brandon Jutras has discovered the cellular component that contributes to Lyme arthritis, a debilitating and extremely painful condition that is the most common late stage symptom of Lyme disease.

Read More: Lyme Disease News and Lyme Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.